Both in Biotechnology
Exelixis vs Kymera Therapeutics
Over the past year EXEL returned +79.4% and KYMR returned +104.8%; their daily moves had a correlation of 0.19.
EXEL +79.4% KYMR +104.8%Growth of $1, one year, split-adjusted
| Metric | EXEL | KYMR |
|---|---|---|
| Price | $69.39 | $126.63 |
| Market cap | $16.93B | $10.81B |
| Today | +4.82% | +3.29% |
| 1 month | +19.8% | +15.0% |
| 6 months | +58.9% | +56.9% |
| Year to date | +58.3% | +62.7% |
| 1 year | +76.0% | +110.9% |
| Revenue growth (YoY) | +10.2% | −100.0% |
| Gross margin | 96.0% | — |
| Net margin | 33.1% | — |
| P/E (TTM) | 19.1× | — |
| Price / sales | 6.8× | 105.7× |
| Net cash | $892.0M | $969.2M |
| Dividend yield | — | — |
| Volatility (60d) | 27.5% | 38.9% |
| Short % of float | 11.4% | 13.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).